Edwards Lifesciences Corp (EW) reports robust 9% sales growth for 2024, driven by TMTT segment and strategic acquisitions, ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...

Buying battle-tested dividend aristocrats can be a winning strategy for those seeking durable retirement income. Read more to ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

An Amber Alert has been issued for a pregnant Wisconsin teen, who police believe is with the 40-year-old man who impregnated ...

HYDERABAD: Doctors at Citizens Hospital successfully treated a 72-year-old patient with severe aortic valve stenosis and ...

Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

JAMESTOWN — Two Sanford Health Fargo cardiology providers offer outreach services at Sanford Jamestown 2nd Ave. Clinic. Outreach services are offered on the second and fourth Wednesday of every month.

Edwards Lifesciences (NYSE: EW) shares got a boost after hours today on fourth-quarter results that came in ahead of the consensus forecast.

Despite guideline recommendations, the use of bioprosthetic heart valves has surpassed mechanical valves, but data from a large surgical database may lead to a reassessment of that practice.

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...